Intralymphatic eASC Administration in Healthy Volunteers
This study has been completed.
Information provided by (Responsible Party):
Cellerix ( TiGenix S.A.U. )
First received: August 24, 2012
Last updated: March 5, 2013
Last verified: February 2013
The objective is to determine the safety, tolerability and feasibility of the inguinal intralymphatic administration of expanded allogeneic adipose-derived stem cells (eASCs)
Localized Adverse Reaction to Administration of Drug
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
||Cx621-0101 Phase I Clinical Trial in Healthy Volunteers to Evaluate the Feasibility and Safety of the Intralymphatic Administration Technique of Expanded Allogeneic Adipose-derived Stem Cells (eASCs)
Primary Outcome Measures:
- Local and systemic reaction to administration procedure [ Time Frame: 29 days ] [ Designated as safety issue: Yes ]
- Pain in administration area will be assessed by a visual analogical scale.
- Medical exploration of the administration area will be performed to identify any skin reaction.
- Inguinal scan will be performed to assess any lymphatic node modification.
- Systemic tolerability will be measured by number of AE (Adverse Event) recorded at any time, including any alteration in laboratory parameters and/or physical exploration.
Secondary Outcome Measures:
- Pharmacodynamic parameters [ Time Frame: 29 days ] [ Designated as safety issue: No ]
- Detection of reactive cells and antibodies against eASC
- Lymphocyte subpopulations studies
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||May 2012 (Final data collection date for primary outcome measure)
- First cohort (3 volunteers, first volunteer is not randomized to detect any acute reaction): injection of 2.5 millions of eASCs suspended in 0.25 ml of HTS per lymph node, total dose 5 millions of cells.
- Second cohort (3 volunteers, first volunteer is not randomized to detect any acute reaction): injection of 5 millions of eASCs suspended in 0.5 ml of HTS per lymph node, total dose 10 millions of cells.
- First cohort: Intra lymph node injection of 2.5 millions of eASCs suspended in 0.5 ml of HypoThermosol per lymph node, total dose 5 millions of cells.
- Second cohort: Intra lymph node injection of 5 millions of eASCs suspended in 0.25 ml of HypoThermosol per lymph node, total dose 10 millions of cells.
Other Name: Allogenic Stem Cells
Placebo Comparator: Placebo
- First cohort (2 volunteers): injection of 0.25 ml of Hypo Thermosol (HTS) per lymph node
- Second cohort (2 volunteers): injection of 0.5 ml of Hypo Thermosol (HTS) per lymph node
- First cohort (2 volunteers): injection of 0.25 ml of HypoThermosol (HTS) per lymph node
- Second cohort (2 volunteers): injection of 0.5 ml of HypoThermosol (HTS) per lymph node
Other Name: HypoThermosol HTS
Phase I, unicentric, single blind, clinical trial with healthy volunteers to determine the feasibility of a new administration technique.
|Ages Eligible for Study:
||18 Years to 55 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Age between 18 and 55 both included
- Inform Consent Form signed
- Body Mass Index (BMI) between 19 and 29 kg/m2
- Presence of, at least, one lymph node of 1cm in its larger diameter in each inguinal location. It has to be accessible for administration after its localization using ultrasound scan.
- Pregnant (positive to urine pregnancy test) or breastfeeding women.
- Subjects with history of any organic or psychic pathology in their records, physical exploration or any complementary test.
- Any relevant current pathology, including cancer, liver pathology, gastrointestinal dysfunction, renal alteration, respiratory pathology or active acute infectious problems.
- Chronic disorders or previous recurrent like hypertension, infections, cardiovascular, respiratory, endocrine, neurologic, hematologic, renal or liver disorders.
- Subjects treated four weeks before the first administration with any drug, medicinal plant or Consumer Health Care in a continue routine. It is not consider exclusion criteria a sporadic medication. The physician will study the interaction between the eASC with this medication.
- History of hypersensibility to drugs.
- Volunteers participants in other clinical trial within 4 months prior the start of the study.
- Blood or derivatives transfusion in 6 months before the trial.
- Known history of abuse of alcohol or other addictive substances(amount of alcohol allow as maximum in this trial is 0.5 liter of wine or two beers or amount in grams equivalent to this of any other alcoholic drink).
- Illegal drugs consumption during the month before the enrollment in the study or positive result to a drug test.
- Positive serology for B hepatitis virus (HbsAg), C hepatitis virus or HIV (Human Inmunodeficiency Virus).
- Subjects whose freedom depends on legal or administrative requirements.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01743222
|Unidad de Investigación Clínica de la Clínica Universidad de Navarra
|Pamplona, Spain, 31008 |
||Belén Sádaba, MD
||Unidad de Investigación Clínica de la Clínica Universidad de Navarra
No publications provided
ClinicalTrials.gov processed this record on September 18, 2014
||Cellerix ( TiGenix S.A.U. )
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 24, 2012
||March 5, 2013
||Spain: Agencia Española de Medicamentos y Productos Sanitarios